PRASOL CHEMICALS — RHP Analysis
Filed with SEBI on
Prasol Chemicals Limited is an established forward-integrated manufacturer of acetone- and phosphorus-based specialty chemicals with two manufacturing units in Maharashtra. The company supplies over 150 products across industrial segments including performance chemicals, agrochemicals, pharmaceuticals, and paints/coatings, generating over 90% of revenue from repeat customers alongside significant export presence across 50+ countries.
Central question
Can Prasol successfully ramp up Mahad facility capacity utilization and commercialize its 40-product developmental pipeline while navigating raw material import price volatility and historical operational disruptions?
Prasol holds strong domestic leadership as the sole Indian manufacturer of isophorone and the largest importer of acetone, creating solid technical stickiness and multi-year customer qualification barriers. However, high raw material import dependence (65.96% in FY26), auditor modifications on internal financial controls, and past safety shutdowns at Mahad remain key monitoring areas.
Offer structure
| Total issue size | ₹500 Cr |
| Fresh issue | ₹80 Cr |
| Offer for sale | ₹420 Cr |
| Price band | ₹643–₹676 |
Debt reduction and general corporate purposes.
Pre-payment or repayment of all or a portion of certain outstanding borrowings availed by the company (₹ 60.00 crore) and general corporate purposes.
What it sells
Who pays: Domestic and global industrial customers across agrochemicals, pharmaceuticals, performance chemicals, paints, inks, construction, adhesives, and personal care.. What it sells: Over 150 specialty chemical products including acetone derivatives, phosphorus derivatives, and other customized specialty chemicals.. How it delivers: Manufactured at two production facilities in Maharashtra (Khopoli and Mahad) and distributed across India and exported to over 50 countries.. How it earns: Direct business-to-business product sales of manufactured specialty chemicals to industrial clients, with over 90% repeat customer orders..
Restated financials
| Period | Revenue | EBITDA | PAT | EPS | ROE |
|---|---|---|---|---|---|
| FY24 | ₹876.57 Cr | ₹18.13 Cr | |||
| FY25 | ₹1,012.49 Cr | ₹43.57 Cr | |||
| FY26 | ₹1,232.59 Cr | ₹83.12 Cr | 14.33 |
Business model
Prasol Chemicals Limited is an established forward-integrated manufacturer of acetone- and phosphorus-based specialty chemicals, operating two production facilities in Maharashtra. Revenue is driven by over 150 products supplied across five primary application segments: performance chemicals, PICA (paints, inks, construction, and adhesives), pharmaceuticals, agrochemicals, and home/personal care. Domestic sales account for over 70% of revenue, with exports reaching customers in over 50 countries.
- Prasol Chemicals manufactures over 150 specialty chemical products across acetone-based, phosphorus-based, and other specialty chemistries. (150+ products, As of June 30, 2026) — Demonstrates product breadth and multi-chemistry manufacturing capability across diverse industrial use cases. [1]
- Raw materials are heavily imported, with imports representing 65.96% of total material procurement costs in Fiscal 2026. (65.96% import share (₹ 5,485.52 million), Fiscal 2026) — Highlights key raw material dependence on global supply chains and foreign currency pricing exposure. [1]
- Repeat customers contribute over 90% of total revenue from operations across the last three fiscal years. (93.28% in Fiscal 2026, Fiscal 2024 to Fiscal 2026) — Reflects customer stickiness and high retention in specialty chemical supply relationships. [1]
Open questions: What is the exact product-level profitability and margin spread across individual acetone and phosphorus derivatives?; What are the specific contract lengths or volume commitments with the top 10 customers given the absence of long-term supply contracts?
Growth thesis
Growth is anchored on capacity utilization ramp-up at Mahad (which operated at only 44.09% in FY26), commercialization of an R&D pipeline comprising 40 developmental products (with 9 past pilot stage), and geographical expansion. The company does not provide explicit forward revenue or profit guidance.
- Capacity utilization at the Mahad Manufacturing Facility reached 44.09% in FY26 following post-incident resumption, leaving substantial headroom from its 19,860 MT annual capacity. (44.09% capacity utilisation (8,756 MT actual production / 19,860 MT capacity), Fiscal 2026) — Ramping utilization from 44.09% towards optimal levels serves as an immediate organic growth driver without major new greenfield capex. [1]
- Prasol maintains an active R&D pipeline of 40 specialty chemical products under development, with 9 products having cleared pilot testing. (40 products in pipeline (9 past pilot), As of June 30, 2026) — Supports portfolio diversification and entry into higher-value derivative chemistries across agrochemical, pharma, and industrial applications. [1]
- Global specialty chemicals market is projected to expand from USD 1,240 billion in CY25 to USD 7.8 trillion across the broader chemicals industry by CY29. (USD 1,240 billion specialty market in CY25, CY2025 to CY2029) — Provides an expanding addressable market backdrop for Indian specialty chemical exporters. [1]
Open questions: What is the projected capital expenditure required to commercialize the 9 products that cleared pilot trials?; When is the Mahad facility expected to reach normalized capacity utilization above 75%?
Offer & ownership
The Offer comprises an aggregate issue of up to ₹ 5,000.00 million, consisting of a Fresh Issue of up to ₹ 800.00 million and an Offer for Sale of up to ₹ 4,200.00 million by Selling Shareholders. The company had 58,000,000 equity shares outstanding prior to the offer, with promoters holding 41.26% directly. Fresh issue proceeds are earmarked primarily for debt pre-payment/repayment of ₹ 600.00 million.
- Pre-offer equity share capital stands at 58,000,000 equity shares of face value ₹ 2 each, aggregating ₹ 116.00 million. (58,000,000 Equity Shares, As of RHP date) — Provides the baseline share count for per-share calculations and dilution assessment. [1]
- Ten identified Promoters collectively hold 23,930,000 equity shares, representing 41.26% of pre-offer equity share capital as first holders. (41.26% (23,930,000 Equity Shares), As of RHP date) — Establishes baseline promoter ownership concentration prior to the IPO. [1]
Open questions: What is the exact post-issue dilution percentage and post-offer share count at the final Offer Price?; What are the specific Selling Shareholder-wise allocations for the ₹ 4,200.00 million OFS component?
Financials
Prasol Chemicals showed strong revenue and margin expansion between Fiscal 2024 and Fiscal 2026. Standalone Revenue from Operations grew from ₹ 8,765.65 million in FY24 to ₹ 12,325.93 million in FY26, with PAT rising from ₹ 181.31 million to ₹ 831.24 million. Operating EBITDA margin improved from 6.91% to 11.30%, while net debt to equity remained conservative at 0.19x in FY26.
- Revenue from operations expanded from ₹ 8,765.65 million in FY24 to ₹ 10,124.94 million in FY25 and ₹ 12,325.93 million in FY26. (₹ 12,325.93 million (FY26), Fiscal 2024 to Fiscal 2026) — Demonstrates compound top-line expansion of 40.6% over the two-year period. [1]
- Restated Profit for the year grew from ₹ 181.31 million in FY24 to ₹ 435.69 million in FY25 and ₹ 831.24 million in FY26. (₹ 831.24 million (FY26), Fiscal 2024 to Fiscal 2026) — Reflects substantial earnings acceleration, with PAT margin rising from 2.07% to 6.74%. [1]
- Total borrowings as of March 31, 2026 were ₹ 1,100.64 million, with Net Debt to Equity at 0.19 times. (Total Borrowings: ₹ 1,100.64 million; Net Debt/Equity: 0.19x, As of March 31, 2026) — Indicates manageable leverage prior to primary proceeds debt pay-down. [1] [2]
- Contingent liabilities and commitments stood at ₹ 1,091.22 million as of March 31, 2026, representing 24.33% of net worth. (₹ 1,091.22 million (24.33% of Net Worth), As of March 31, 2026) — Highlights off-balance sheet obligations, largely comprised of letters of credit and guarantees. [1]
- As at March 31, 2026, total assets stood at ₹8,392.75 million. (₹8,392.75 million, As at March 31, 2026) — Discloses the total asset base of the company on a standalone basis at the end of Fiscal 2026. [1]
- As at March 31, 2025, consolidated total assets stood at ₹7,230.87 million. (₹7,230.87 million, As at March 31, 2025) — Discloses the consolidated asset base of the company at the end of Fiscal 2025. [1]
- As at March 31, 2024, consolidated total assets stood at ₹6,263.57 million. (₹6,263.57 million, As at March 31, 2024) — Discloses the consolidated asset base of the company at the end of Fiscal 2024. [1]
- As at March 31, 2026, total equity stood at ₹4,485.05 million. (₹4,485.05 million, As at March 31, 2026) — Discloses the total equity capital and reserves of the company on a standalone basis as of March 31, 2026. [1]
- As at March 31, 2025, consolidated total equity stood at ₹3,674.70 million. (₹3,674.70 million, As at March 31, 2025) — Discloses the consolidated total equity of the company as of March 31, 2025. [1]
- As at March 31, 2024, consolidated total equity stood at ₹3,258.35 million. (₹3,258.35 million, As at March 31, 2024) — Discloses the consolidated total equity of the company as of March 31, 2024. [1]
Open questions: Why did the restated presentation transition from Consolidated in FY24-FY25 to Standalone in FY26 following the strike-off of the sole subsidiary?; What drove the sharp decline in operating cash flows in FY25 compared to FY24 despite higher PAT?
Moat & defensibility
Prasol Chemicals derives defensibility from substantial market position as the sole domestic producer of isophorone and the largest Indian importer of acetone, alongside high switching costs created by 1–4 year customer approval cycles. However, defensibility is counterbalanced by lack of long-term supply contracts and reliance on non-exclusive customer relationships.
- Prasol Chemicals was the largest importer of acetone in India and the only domestic manufacturer of isophorone between 2022 and 2025. (CY2022 - CY2025) — Establishes a strong niche manufacturing moat and volume scale advantage in acetone derivatives within India. [1]
- Customer approval and qualification cycles in specialty chemicals require 1 to 4 years of testing, establishing high supplier stickiness. (1-4 years approval cycle, Offer document disclosure) — Creates substantial switching costs and technical barriers against potential new entrants. [1]
- Prasol faces intense competition in global export markets from multinational players such as Arkema, Evonik, TASCO, Solvay, and Hubei Xingfa. (Offer document disclosure) — Demonstrates that export defensibility is constrained by global chemical majors with larger scale and integration. [1]
Open questions: What share of customer accounts have dual-sourcing arrangements that could dilute switching costs?; How proprietary are the chemical synthesis processes relative to unpatented standard chemical engineering methods?
Governance
The Board comprises 10 directors, evenly split between 5 Executive Directors and 5 Non-Executive Independent Directors, including 1 woman independent director. Executive management remuneration is linked to base salary plus performance-linked bonus capped at specific percentages of PBT. Related party transactions include key management remuneration, family relations in senior roles, and past land acquisition from promoter-directors.
- The Board is composed of 10 Directors, comprising 5 Executive Directors and 5 Non-Executive Independent Directors. (10 Directors (5 Executive, 5 Independent), As of RHP date) — Confirms board structure compliance with SEBI Listing Regulations on independent representation. [1]
- The Chief Financial Officer & Finance Director, Rahul Ashit Shroff, is the son-in-law of Chairman & Whole-time Director Nishith Rajnikant Shah. (As of RHP date) — Highlights family relationships within key executive leadership positions. [1]
- Prasol acquired land from Dhaval Nalin Parikh and other promoter confirming parties for ₹ 44.10 million in January 2022 to meet MoEFCC environmental clearance requirements. (₹ 44.10 million, January 20, 2022) — Highlights significant related-party property transaction with promoter-directors. [1]
Open questions: What specific performance criteria determine the executive directors' variable bonus payouts beyond the PBT caps?; Are there any ongoing related party transactions with entity Consolidated Chemequip (MFR) Private Limited beyond MEIS/RODTEP license purchases?
Risks
Key operational risks center on manufacturing hazards, regulatory environmental enforcement, and history of plant shutdowns. The Mahad facility was closed for over 6 months following a fatal toxic gas leak in October 2023, resulting in criminal proceedings against Managing Director Gaurang Parikh. Statutory auditors have issued emphasis of matter and modified opinions on internal financial controls.
- Statutory auditors included emphasis of matter and modified opinions regarding internal financial controls across Fiscals 2024, 2025, and 2026. (Fiscals 2024, 2025, 2026) — Underlines material weaknesses in internal control mechanisms over financial reporting. [1]
Open questions: What specific remediation was completed to address the modified audit opinion on internal financial controls?; What is the maximum potential personal and corporate exposure if the ongoing criminal safety proceedings result in adverse rulings?
Valuation framework
Valuation inputs are incomplete as the Price Band, Issue Price, Floor Price, Cap Price, and post-issue capitalisation numbers remain unannounced in this Red Herring Prospectus. Reported Diluted EPS for FY26 is ₹ 14.33, Net Asset Value per share is ₹ 77.33 as of March 31, 2026, and Return on Net Worth is 18.53%. Listed peer P/E multiples on August 28, 2026 range from 17.12x (Excel Industries) to 206.68x (Yasho Industries) with a peer average of 61.74x.
- NAV per Equity Share was ₹ 77.33 as of March 31, 2026, and Return on Net Worth was 18.53% for FY26. (NAV: ₹ 77.33; RoNW: 18.53%, As of March 31, 2026) — Key balance-sheet and return efficiency metrics for comparison with peer group valuations. [1] [2]
- Listed industry peers trade at FY26 P/E ratios ranging between 17.12x and 206.68x, with an arithmetic average of 61.74x as of August 28, 2026. (Average Peer P/E: 61.74x (Range: 17.12x - 206.68x), As of August 28, 2026) — Provides the external market pricing spectrum across specialty chemical peers (Aarti, Atul, Laxmi Organic, Vinati, Privi, Yasho, Excel). [1]
Open questions: What will be the final Floor Price and Cap Price announced prior to issue opening?; What will be the implied post-money market capitalisation and trailing P/E at the Cap Price?
What the filing leaves open
- This document is a Red Herring Prospectus containing undisclosed pricing placeholders ([●]) for the Price Band, issue share counts, and post-issue capitalisation.
- Financial information for Fiscal 2026 is presented on a Standalone basis following the voluntary strike-off of Prasol Aromatics Private Limited, whereas Fiscals 2024 and 2025 are Consolidated.
- No forward financial guidance (revenue, EBITDA, PAT, EPS) is provided by the issuer, precluding deterministic forward multiple calculation.